| Finished Dosage (FD) | Generic finished pharmaceuticals, oral solids, peptides, specialty formulations. | Vertical integration, strong USFDA approvals, R&D pipeline, exclusive peptide CDMO capabilities. | Primarily B2B with increasing B2C OTC sales in North America; global pharmaceutical firms as partners. | Complex generics and peptide manufacturing segments. | 14200 | 65 | Sales to global pharma companies, direct supply to US retail chains, licensing of specialized products. | Product sales contracts, tiered pricing in generics, licensing revenues. | ANDA approvals, new product launches, complex and integrated generics expansion, peptide CDMO growth. | Ascelis Peptides, Metformin XR, Colchicine Capsules |
| Pharmaceutical Formulation Intermediate (PFI) | Bulk intermediates for formulation manufacturing. | Integrated supply chain improves cost and quality control. | Pharmaceutical manufacturers globally (B2B). | Advanced intermediates for proprietary formulations. | 3200 | 14 | Sales contracts to formulations businesses worldwide. | Volume-based supply contracts. | Backward integration, capacity expansion, and regulatory approvals. | Paracetamol DC blends, Salbutamol Sulphate PFI |
| Active Pharmaceutical Ingredient (API) | Active pharmaceutical ingredients for generics and branded drugs. | Large-scale, FDA-compliant facilities with backward integrated raw material sourcing. | Pharma companies globally (B2B). | Specialty APIs and newly developed cost-efficient APIs. | 4400 | 20 | Long-term supply agreements, tender-based sales. | Contract manufacturing and tender pricing. | New API developments, capacity expansions, global demand for generics. | Paracetamol API, Ibuprofen API, Metformin API |
